Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma
Metrics: PDF 2450 views | HTML 3346 views | ?
Yi Cai1, Sonam Dodhia1 and Gloria H. Su1,2,3
1 Department of Otolaryngology-Head and Neck Surgery, Columbia University Medical Center, New York, NY, USA
2 Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
3 Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA
Gloria H. Su, email:
Keywords: PI3K signaling, head and neck squamous cell carcinoma, PIK3CA mutation, PI3K inhibitor, personalized medicine
Received: October 15, 2016 Accepted: January 09, 2017 Published: January 18, 2017
The phosphoinositide 3-kinase (PI3K) signaling pathway is the most commonly mutated pathway in head and neck squamous cell carcinoma (HNSCC). There are several drugs targeting members of the PI3K signaling pathway in development for HNSCC. In this article, we review the genetic alterations reported in the pathway pertinent to HNSCC, various agents in development targeting various mediators of the pathway, results from clinical trials, and remaining challenges in the development of PI3K pathway inhibitors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.